跳到正文
原文
Endpoints News 生物医药· Nicole DeFeudis·· 26 天前精选AI 评分68

ivonescimab胆道癌III期临床试验结果公布及与Keytruda对比分析

#ESMO26: Akeso details ivonescimab's biliary cancer success, drawing Keytruda comparisons

AI 导读

ivonescimab在胆道癌III期临床试验中显示中位总生存期(OS)和疾病进展间隔(PFS)优势,Akeso与Summit Therapeutics公布该中国专属适应症数据,并与Keytruda疗效指标形成对比。原文未提供具体数值,但明确提及试验为随机对照试验(RCT)。

推荐理由

ivonescimab在胆道癌III期临床试验中显示生存期优势,与Keytruda的对比为后续适应症拓展提供参考视角。

正文

MADRID — Ake­so on Sun­day spelled out by how much its Sum­mit Ther­a­peu­tics-part­nered PD-1xVEGF bis­pe­cif­ic im­proved sur­vival in a late-stage, Chi­na-on­ly bil­iary tract can­cer study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news